T Cell‐Mediated Cytotoxicity Against p53‐Protein Derived Peptides in Bulk and Limiting Dilution Cultures of Healthy Donors

Scandinavian Journal of Immunology

Volumn 42, Issue 1, 1995, Pages 98-103

  ROPKE M ^a   REGNER, M ^a   CLAESSON, M H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; PROTEIN P53; RECOMBINANT INTERLEUKIN 2;

ADULT; ARTICLE; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR SUPPRESSOR GENE;

ADULT; AMINO ACID SEQUENCE; CELLS, CULTURED; CYTOTOXICITY TESTS, IMMUNOLOGIC; EPITOPES; HLA-A2 ANTIGEN; HUMAN; LYMPHOCYTE COUNT; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN P53; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0029032763     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.1995.tb03631.x     Document Type: Article

References (23)

1. p53 mutations in human cancers
2. Cancer. p53, guardian of the genome
3. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot
4. Analysis of p53 antibodies in patients with various cancers define B‐cell epitopes of human p53: distribution on primary structure and exposure on protein surface
5. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53
6. The transport of class I major histocompatibility complex antigens is determined by sequences in the alpha 1 and alpha 2 protein domains
7. Allele‐specific motifs revealed by sequencing of self‐peptides eluted from MHC molecules
8. Prominent role of secondary anchor residues in peptide binding to HLA‐A2.1 molecules
9. Cloning and characterization of a cDNA from Xenopus laevis coding for a protein homologous to human and murine p53
10. The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA‐A2
11. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis
12. TP53 tumour suppressor gene: a model for investigating human mutagenesis
13. A quantitative assay to measure the interaction between immunogenic peptides and purified class I major histocompatibility complex molecules
14. p53, a potential target for tumour‐directed T cells
15. + cytotoxic T cell
16. How cytotoxic T cells manage to discriminate nonself from self at the nonapeptide level
17. Quantitative studies on T cell diversity. I. Determination of the precursor frequencies for two types of streptococcus A‐specific helper cells in nonimmune, polyclonally activated splenic T cells
18. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
19. A nonapeptide encoded by human gene MAGE‐1 is recognized on HLA‐A1 by cytolytic T lymphocytes directed against tumour antigen MZ2‐E
20. Identification of the immunodominant peptides of the MART‐1 human melanoma antigen recognized by the majority of HLA‐A2‐restricted tumour infiltrating lymphocytes
21. In vitro generation of human cytolytic T‐cells specific for peptides derived from the HER‐2/neu protooncogene protein
22. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells
23. Frequency analysis of tumour‐reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumour cells